Why Is Inovio Pharmaceuticals (INO) Stock Up +2.43% Today?
Key Takeaways
- INO shares rose 2.43% to $0.922 in Friday mid-morning trading, extending the prior session's 16.9% surge.
- The advance follows better-than-expected second-quarter results and an upbeat update on the FDA review of lead candidate INO-3107.
- Jefferies upgraded the stock to Buy from Hold and lifted its price target to $3.00 from $1.80, citing regulatory progress.
- The FDA has completed its late-cycle review and pre-licensure inspections, with a PDUFA target action date of October 30, 2026.
- Trading volume has run well above average, signaling elevated investor interest in the small-cap biotech name.
- Investors are watching for FDA label negotiations in September and feedback on the confirmatory trial design.
Opening Summary
Inovio Pharmaceuticals, Inc. (INO), a clinical-stage biotechnology company focused on DNA medicines, saw its stock climb 2.43% to $0.922 in Friday mid-morning trading, up from the prior close of $0.9001. The move extends a powerful two-day rally for the small-cap biotech, which had already surged 16.9% on Wednesday after second-quarter results and a Street upgrade. Market participants attributed the continued buying to momentum around the FDA's advancing review of INO-3107, the company's investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, and to a narrower-than-expected quarterly loss.
FDA Review Momentum for INO-3107
The primary catalyst behind the move is regulatory. Inovio said the FDA has completed its late-cycle review meeting and all scheduled pre-licensure inspections for INO-3107, covering clinical sites, drug manufacturing, internal testing, and the delivery-device facility. The agency reported one inspection observation, which management said has been addressed. The review keeps the PDUFA target action date of October 30, 2026, on track, and the company expects label discussions to begin in September. Although the FDA has not yet signaled whether INO-3107 qualifies for accelerated approval, the completion of key review steps has reduced a layer of uncertainty that had weighed on the stock.
Second-Quarter Results and Cost Discipline
The stock's move is also earnings-driven. After the close on August 12, Inovio reported a second-quarter net loss of $6.0 million, or $0.07 per share, versus a loss of $23.5 million, or $0.61 per share, a year earlier. The result beat Wall Street expectations, though much of the improvement reflected a noncash fair-value gain on warrant liabilities. Operating expenses fell 19% year over year to $18.6 million. The company ended the quarter with $36.7 million in cash and short-term investments and added roughly $18.3 million in July offering proceeds, extending its projected cash runway into late first-quarter 2027.
Analyst Upgrade Adds Fuel
Fresh Street support amplified the rally. Jefferies upgraded INO to Buy from Hold and raised its price target to $3.00 from $1.80, pointing to the FDA review's progress and management's confidence that INO-3107 meets accelerated-approval criteria. H.C. Wainwright separately reiterated a Neutral rating with a $2.50 target. Positive Phase 3 data from partner ApolloBio for VGX-3100 in cervical dysplasia in China provided additional pipeline validation.
Market Context and Trading Activity
The move has been stock-specific rather than a broad biotech-sector rally. Wednesday's advance occurred on turnover of more than 12 million shares, roughly double Inovio's average daily volume of about 5.5 million, and Friday's session opened with elevated activity. The rebound has carried the shares roughly 38% above their August 7 close of $0.668, and early Friday buying briefly pushed the stock up as much as about 7% before it pared gains. Even so, the shares remain far below the 52-week high of $2.9789, reflecting the high-risk, catalyst-driven nature of the name.
What Comes Next for INO
The next major catalyst is the FDA's decision on INO-3107, with a PDUFA target action date of October 30, 2026. Before that, investors will watch for label negotiations in September and the agency's feedback on the confirmatory trial design. Key risks include whether the FDA grants accelerated approval, the commercial ramp against an existing RRP treatment, and the potential for further capital raises after the company's projected cash runway into late first-quarter 2027. Quarterly operational updates and any partnership announcements for the broader DNA-medicine pipeline may also shape sentiment.
Trending AI Robots
For traders scanning the market for systematically driven opportunities, Tickeron's Trending AI Robots page highlights a curated group of AI-powered trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this Trending AI Robots section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore different approaches. Consider reviewing the page to see which automated strategies are currently gaining traction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INO in +17.54% Uptrend, rising for three consecutive days on August 13, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where INO advanced for three days, in of 233 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INO's RSI Oscillator exited the oversold zone, of 51 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 60 cases where INO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 13, 2026. You may want to consider a long position or call options on INO as a result. In of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for INO just turned positive on August 13, 2026. Looking at past instances where INO's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
INO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for INO entered a downward trend on August 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.026) is normal, around the industry mean (20.281). P/E Ratio (0.000) is within average values for comparable stocks, (25.508). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.845). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (437.072).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. INO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of synthetic vaccines and immune therapies for cancers and infectious diseases
Industry Biotechnology
Advertisement